Delayed Maturation of Antibody Avidity but Not Seroconversion in Rhesus Macaques Infected With Simian HIV During Oral Pre-Exposure Prophylaxis

作者：Curtis Kelly A^*; Kennedy M Susan; Luckay Amara; Cong Mian er; Youngpairoj Ae S; Zheng Qi; Smith James; Hanson Debra; Heneine Walid; Owen S Michele; Garcia Lerma J Gerardo

来源：JAIDS: Journal of Acquired Immune Deficiency Syndromes , 2011, 57(5): 355-362.

DOI：10.1097/QAI.0b013e3182234a51

• HIV antibodies
• HIV infections
• animal models
• pre-exposure prophylaxis
• anti-HIV agents

Background: Pre-exposure prophylaxis (PrEP) is a novel intervention strategy for the prevention HIV transmission. Because several clinical trials are at various stages of completion, it is important to understand the impact of PrEP treatment on the development of the immune response to HIV, particularly in individuals who exhibit breakthrough infections despite PrEP.
Methods: A model of HIV infection, using rhesus macaques and the simian/human immunodeficiency virus (SHIV), was used to evaluate the effects of PrEP on the evolution of the humoral immune response. Time to seroconversion, neutralizing and binding antibody levels, and antibody avidity were measured in 12 rhesus macaques infected during daily or intermittent PrEP with FTC (emtricitabine) or Truvada (FTC/tenofovir combination) and compared with 11 untreated, simian HIV-infected controls.
Results: Macaques that became infected while receiving PrEP exhibited significantly lower peak virus loads during acute infection as compared with untreated animals. Although the timing of seroconversion and SHIV binding and neutralizing antibody levels were not impacted by treatment, lower maturation rates of antibody avidity for anti-p27, gp120, gp160, and gp41 were observed.
Conclusions: This study suggests that reduced virus loads associated with PrEP treatment have little impact on timing of seroconversion and neutralizing/binding antibody levels; however, maturation of antibody avidity was suppressed.

• 出版日期2011-8-15